Viewpoint Molecular Targeting
Latest round
- Series A
Last raised
- Nov 2020
Total raised
- $13M
Investors
- 1
About Viewpoint Molecular Targeting
, operates as a developer of pharmaceutical drugs and therapies intended for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. In January 2021, Viewpoint Molecular Targeting, Inc., SpectronRx, and many more. The company offers various pharmaceutical solutions that include alpha-particle theranostics used to reveal cancer cells in the body. The company’s targeted alpha therapies include pipelines like Pb-203, Pb-212, bismuth-212, polonium-212, and thallium-208, which help cancer-killing alpha-particle radiation be used for energy, medical, national security, and basic research. The company's product targets a cell surface receptor that is found on the cell surface of metastatic melanoma cells and can be used to determine the location and extent of cancerous tumours in the body, enabling health professionals to direct a lethal dose of radiation precisely to cancer cells in the body.
Who invested in Viewpoint Molecular Targeting
1 investor across 1 round
See all investors in Viewpoint Molecular Targeting
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 20, 2020
Amount
$13M
Investors
Questions about Viewpoint Molecular Targeting
Who invested in Viewpoint Molecular Targeting?
Viewpoint Molecular Targeting has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Viewpoint Molecular Targeting raised?
Viewpoint Molecular Targeting has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Viewpoint Molecular Targeting last raise money?
Viewpoint Molecular Targeting's most recent round on record is a Series A, in Nov 2020.
What does Viewpoint Molecular Targeting do?
, operates as a developer of pharmaceutical drugs and therapies intended for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma.
Where is Viewpoint Molecular Targeting headquartered?
Viewpoint Molecular Targeting is headquartered in Coralville, US.
Which VCs invest in companies like Viewpoint Molecular Targeting?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Viewpoint Molecular Targeting's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Viewpoint Molecular Targeting? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.